Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma

BACKGROUND: Surgery is the primary treatment for basal cell carcinoma (BCC). In locally advanced basal cell carcinoma (laBCC), surgery may cause functional or aesthetic damage. In laBCC, neoadjuvant administration of vismodegib, an inhibitor of the Hedgehog signaling pathway, may reduce tumor size,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EClinicalMedicine
Autors principals: Bertrand, Nicolas, Guerreschi, Pierre, Basset-Seguin, Nicole, Saiag, Philippe, Dupuy, Alain, Dalac-Rat, Sophie, Dziwniel, Véronique, Depoortère, César, Duhamel, Alain, Mortier, Laurent
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2021
Matèries:
Research paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8093898/
https://ncbi.nlm.nih.gov/pubmed/33997740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100844
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars